Bone marrow mesenchymal stem/stromal cells (BM-MSCs) can infiltrate into tumors and subsequently evolve into tumor resident MSCs in tumor microenvironment. In this study, using a mouse lymphoma model, we showed that the lymphoma resident MSCs (L-MSCs) are able to confer tumor-promoting property to the naïve cocultured BM-MSCs. Examination of cytokines and chemokines showed that post exposure to L-MSCs, BM-MSCs acquired an expression profile that is similar to that in L-MSCs. In vivo, BM-MSCs educated by L-MSCs (BM-L-MSCs) possess a greatly enhanced ability in promoting lymphoma growth. Consistent with an elevated CCL-2 expression in BM-L-MSCs, the tumor-promoting effect of BM-L-MSCs largely depends on CCR2-mediated macrophage recruitment to tumor sites. We further showed that the transmission of tumor-promoting effect is partially mediated by soluble factors. Our findings thus revealed a novel reinforcing mechanism in the maintenance of tumor microenvironment.
INTRODUCTION
The tumor microenvironment comprises multiple types of noncancer cells, including endothelial cells, immune cells, fibroblasts and recently accentuated mesenchymal stem/stromal cells (MSCs). [1] [2] [3] Although non-cancer stromal cells themselves do not initiate neoplastic transformation, they have crucial roles in tumor promotion and progression. 4, 5 Previous studies have revealed bidirectional interactions between tumor cells and tumor microenvironment through cytokines, chemokines, adhesion molecules, and small RNAs. 1, [6] [7] [8] However, little is known about whether established tumor stromal cells could influence newly recruited stromal cells. In this study, we showed that tumor stromal cells can endow naïve stromal cells with tumor-promoting properties.
MSCs, regarded as precursors of tumor-associated fibroblasts, are emerging as one of the major components of the tumor microenvironment. 9, 10 These tumor MSCs actively participate in both primary tumor progression and tumor metastasis. They have been shown to be capable of producing tropic factors and enzymes, implementing immunosuppression, modulating epithelialmesenchymal transition and contributing to the creation of cancer stem cell niches in various cancer types including breast cancer, ovarian cancer, pancreatic cancer, lymphoma and melanoma. 2, 3, [11] [12] [13] [14] Previous studies from ours and other laboratories have shown that MSCs are capable of migrating to primary tumor sites during tumor development. 3, 15 At the tumor sites, the tumor-associated inflammatory environment converts newly arrived MSCs into tumor resident MSCs that display distinct properties, especially a strong tumor-promoting activity. 3 We demonstrated that compared with bone marrow mesenchymal stem/stromal cells (BM-MSCs), lymphoma derived MSCs (L-MSCs) are more potent in enhancing the growth of transplanted tumors due to a great elevation in the expression of CCR2 ligands (CCL-2, CCL-7 and CCL-12) that recruit macrophages/ monocytes to the tumor sites. Depletion of macrophages/ monocytes or deficiency in CCR2 abrogated the tumorpromoting activity of L-MSCs, indicating a crucial link between lymphoma resident MSCs and tumor infiltrating macrophages/ monocytes. 3 Importantly, consistent with the findings in our mouse models, a recent study showed that MSCs infiltrated in human follicular lymphomas also support tumor growth through a CCL-2-dependent polarization of inflammatory monocytes. 16 Therefore, tumor resident MSCs are functionally distinct from normal tissue MSCs, such as those in bone marrow. Considering that there is a constant trafficking of tissue MSCs into the tumor sites, we investigated whether tumor resident MSCs have an impact on the newly recruited MSCs in vitro and in vivo.
RESULTS AND DISCUSSION
MSCs tend to migrate to the tumors during tumor progression. We then wondered how these freshly recruited MSCs are influenced by the tumor microenvironment. It is well-known that tumor cells, tumor-associated inflammatory cells and cytokines in the tumor microenvironment can potentially have an impact on tumor stromal cells. 17 We asked whether established tumor resident
MSCs/stromal cells could also educate newly arrived MSCs/stromal cells at the tumor site. This issue is critical, especially when considering that there is a constant trafficking of MSCs from bone marrow (or other tissues) into tumor sites. To test this, we cocultured previously established L-MSCs 3 with primary BM-MSCs (derived from GFP-transgenic mice). After four passages of coculture, the GFP þ BM-MSCs were isolated by flow cytometrybased cell sorting. These educated MSCs, designated as BM-MSCs educated by L-MSCs (BM-L-MSCs), were then compared with control BM-MSCs and control L-MSCs, which had undergone the same number of passages and cell sorting procedures, in their gene expression and their capacity in promoting tumor growth in vivo. Our experiment protocols are outlined in Figure 1a . The representative data shown below were from BM-L-MSCs obtained by coculturing GFP þ BM-MSCs with a L-MSC line derived from a lymphoma in p53 þ / À mouse. Similar results were obtained with other L-MSC lines. All MSCs were determined to have capability to differentiate into adipocytes and osteoblasts, 18 and were examined for the expression of cell-surface differentiation markers.
We previously reported that L-MSCs were distinct from BMMSCs mainly in their secretomes, especially in expression of certain chemokines and cytokines. 3 To determine if L-MSC coculture could lead to changes in BM-MSCs, we analyzed, by real-time PCR-based gene arrays, the expressions of major inflammatory cytokines, chemokines and their receptors in freshly sorted BM-L-MSCs, BM-MSCs and L-MSCs. Consistent with our previous report, 3 the expression levels of many chemokines, especially the CCR2 ligands CCL-2, CCL-7 and CCL-12, were much higher in L-MSCs than in BM-MSCs (Table 1) . Intriguingly, BM-LMSCs exhibited a cytokine/chemokine expression pattern similar to that in L-MSCs, also with dramatically higher levels of expression of CCL-2 (450-fold), CCL-7 (410-fold), CCL-5 (440-fold), CCL-12 (420-fold) and CXCL10 (450-fold), in comparison to control BM-MSCs at the same passages (Table 1) . In contrast to the remarkable elevation in the expressions of the chemokine/ cytokine ligands in BM-L-MSCs, the expressions of chemokine/ cytokine receptors were not found to differ significantly between BM-L-MSCs and BM-MSCs at both the mRNA and the protein levels (Supplementary Table 1 and Supplementary Figure 1) . Consistent with the gene transcription pattern revealed by real-time PCR, freshly sorted BM-L-MSCs were also found to produce a much higher level of chemokines and cytokines at the protein level, especially CCL-2, as determined by a multiplex beads-based protein array and enzyme-linked immunosorbent assay (Figure 1b) . Therefore, exposure to L-MSCs enabled BM-MSCs to acquire a new chemokine and cytokine expression phenotype.
We next determined whether the altered gene expression in BM-L-MSCs is accompanied by changes in tumor-promoting capability in vivo. Using a mouse lymphoma model described previously, 3 we coadministered EL4 T-cell lymphoma cells with freshly sorted BM-L-MSCs, control BM-MSCs or control L-MSCs in C57BL/6J mice. As shown in Figure 2a , BM-L-MSCs were able to promote EL4 lymphoma growth almost to the same level as L-MSCs did. When the tumors were excised for examination of immune cell infiltration, we observed that F4/80 þ macrophages were much more abundant in tumors receiving either BM-L-MSCs or L-MSCs than those received BM-MSC (Figure 2b ). This tumorpromoting effect and the macrophage-recruiting function of BM-L-MSCs corresponded well to their high expression levels of CCR2 ligands (Table 1 and Figure 1b) , the major macrophage chemokines. More interestingly, the macrophages infiltrated in the tumors from either BM-L-MSC or L-MSC co-injection groups showed an M2-like phenotype with elevated interleukin (IL)-10 expression and decreased IL-12 expression (Supplementary Figure 2) . These phenotypic changes may be caused by local macrophage polarization through tumor stromal education or preferential recruitment of M2 macrophages by MSCs, which requires elucidation in future studies. Thus, BM-MSCs educated by L-MSCs gained an enhanced capacity in recruiting macrophages and in promoting tumor growth in vivo.
To further determine whether the acquired tumor-promoting phenotype of BM-L-MSCs was indeed dependent on CCR2 ligands and macrophages, we performed the EL4 lymphoma transplantation experiment in CCR2 -/-mice and in macrophage-depleted mice (using CD11b-DTR transgenic mice). Clearly, either CCR2 deficiency (Figure 3a) or depletion of macrophages (Figure 3b ) completely abrogated the tumor-promoting effect of BM-L-MSCs, indicating that the enhancement in CCR2-mediated macrophage recruitment was primarily responsible for the acquired tumor-promoting property of BM-L-MSCs. Therefore, when BM-MSCs, or other naïve tissue stromal cells, are recruited to the tumor sites, the tumor resident MSCs can convert them from naïve bystanders to strong tumor promoters.
We next explored the mechanism through which tumor resident MSCs influence the newly recruited BM-MSCs. We first examined whether cell-cell contact is required for the transmission of the tumor-promoting property from L-MSCs to naïve MSCs. By using a transwell coculture system, we were able to measure the CCL-2 expression in BM-MSCs that had been kept from direct contact with L-MSCs for three passages. The expression level of CCL-2 in BM-MSCs was increased more than 20-fold after coculture with L-MSCs in transwells (Figure 3c ), although such an increase was not as dramatic as in direct cell-cell contact (Table 1 ). This result indicates that soluble factors secreted from L-MSCs at least have a partial role in educating BM-MSCs. Accordingly, L-MSC conditioned media was also able to stimulate the CCL-2 expression in BM-MSCs (Figure 3d ). As CCL-2 showed the greatest difference in its expression level between L-MSCs and BM-MSCs and functions as the major tumor-promoting factor for its role in macrophage recruitment, we therefore wondered whether this chemokine contributed to the conversion from BMMSCs to BM-L-MSCs. However, neutralizing antibody to CCL-2 in the L-MSC conditioned media did not alter the CCL-2 gene expression in BM-MSCs (Figure 3d ), suggesting that soluble factors other than CCL-2 were responsible for the converging effect of L-MSCs.
In summary, our studies revealed a novel stroma-stroma interaction for reinforcing the maintenance of tumor 5 cells/ml), which was then added to the BM-MSC cells (passage 3, 2 Â 10 5 cells/ml). Anti-mouse CCL-2 (20 mg/ml) or its corresponding isotype IgG was supplemented in the cultures. Two days later, the CCL-2 gene expression of these three groups of cells was determined by real-time PCR. All results were representative of three independent experiments. **Po0.01 and ***Po0.001.
